Thursday, 31 October 2019

Investorideas.com - Cannabis Stock News: Beleave (CSE: BE) (OTC: BLEVF) Announces Joint Venture with Volero Brands to Launch Cannabis 2.0 Products in Canada

Investorideas.com - Cannabis Stock News: Beleave (CSE: BE) (OTC: BLEVF) Announces Joint Venture with Volero Brands to Launch Cannabis 2.0 Products in Canada

Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV: $VGW.V) (NASDAQ: $SNDL) (TSXV: $GYSR.V) (NYSE: $ACB) (OTC: $OWPC)


Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV: $VGW.V) (NASDAQ: $SNDL) (TSXV: $GYSR.V) (NYSE: $ACB) (OTC: $OWPC)



Delta, Kelowna, BC –October 31, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:



Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts

In today’s podcast we look at a few early announcements.

But first, Kanvas™, creator of innovative solutions designed to elevate the user experience for legal cannabis and cannabidiol (CBD) consumers, announced its Child-Resistant Disposable Vaporizer is the first all-in-one hardware solution to pass stringent child-resistant testing, delivering the market’s first certified child-resistant complete vape device.
Dedicated to consumer vape safety, Kanvas engineered the first-of-its-kind child-resistant vape pen utilizing an ingenious push-and-turn technology that disengages the battery to prohibit device operation. This patent-pending complete child-resistant solution was tested by an accredited laboratory to meet the Consumer Product Safety Commission’s (CPSC) standards for child-resistant packaging as stated in the Code of Federal Regulations Title 16, Section 1700.20. Additional benefits of Kanvas’ fail-safe design include prolonged battery life, auto-firing restriction and protection from the very first hit.
“We are proud to be the first in our industry to introduce an end-to-end vape solution with certified child-resistant functionality,” said Andy Fathollahi, Kanvas CEO. “Unlike devices from other hardware manufacturers, the Kanvas Child-Resistant Disposable Vaporizer is the first and only complete device that offers peace of mind out of the box. We have a tremendous engineering department that worked tirelessly to make our goal of child safety in the vape category a reality.”
The Child-Resistant Disposable Vaporizer is powered by Vapetelligence™, Kanvas’ exclusive temperature-controlled dosing technology, and secured with a DualLock snap-on compression fit mouthpiece that eliminates tampering and leaks. Composed of food-grade 18/10 stainless steel and a ceramic core, its undetectable levels of heavy metals are 10 times lower than the industry standard.


Valens GroWorks Corp. (TSXV: VGW) (OTCQX: VGWCF), a vertically integrated provider of industry leading extraction products and services; including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab announced a multi-year white label agreement with BRNT Ltd, a leading, premium, cannabis ancillary company to launch a line of unique cannabis vape pens in Canada. Under the terms of the Agreement, Valens will provide high-quality cannabis extracts, filling services and national distribution of a line of custom-formulated BRNT-branded vape pens.

The initial term of the Agreement will be for two years, with two successive one year renewal options, and relates to the production and sale of a guaranteed minimum of 2.2 million BRNT-branded vape pens, with the gross revenue potential to Valens under the Agreement of over $50 million in the first two years, all subject to final acceptance from provincial distributors, including of the proposed price per unit. Under the terms of the Agreement, the two parties will split economics through a profit share structure reflective of the respective efforts of each party.  Valens expects the first shipment under the Agreement to take place in the first fiscal quarter of 2020. The Company currently holds all required licensing from Health Canada to carry out its obligations under the Agreement.
BRNT is known for its rapid national growth, brand quality, industry experience and commitment to product excellence. BRNT currently participates in the ancillary products sector providing premium, high-quality cannabis accessories that are currently available in over 170 stores across Canada with international expansion underway including its newest line, Made By: a line of single-source cannabis extract vaporizers with uniquely designed hardware.

"As Valens begins official production of next generation products for Cannabis 2.0, we are excited to be collaborating with BRNT to bring to market a line of differentiated, high quality, concentrate vape products for Canadian consumers", said Tyler Robson, CEO of Valens GroWorks. "BRNT has shown impressive sales growth and market understanding through its ancillary offerings. In pairing their retail and product knowledge with Valens' processing and product development capabilities we believe this provides a solid foundation to provide a product with strong consumer appeal."

"Valens has demonstrated a commitment to cannabis extraction on a global scale that is driven by passion and quality. It was a natural fit for BRNT to collaborate with Valens to bring the Made By vaporizers brand to life with a partner that can mirror our globally recognized signature design aesthetic and brand development capabilities," said Simon Grigenas, CEO of BRNT Group. "BRNT and Valens are setting a new industry standard by creating meaningful brands and products through a focused, profitable approach, as opposed to the traditional vertical integration seen today."

Sundial Growers Inc. (NASDAQ: SNDL) has successfully entered the Prince Edward Island market, highlighting its intent to be in all Canadian provinces by the end of 2019. Sundial's products are now available in seven provinces.

The company recently announced that it will release its third quarter financial results on November 13, 2019 after Nasdaq market closing.

"P.E.I. has proven to have a keen cannabis culture, and we are looking forward to meeting the province's strong consumer demand for high-quality cannabis products," said Andrew Stordeur, President of Sundial's Canadian operations. "Islanders are sophisticated consumers who want a wide range of products to choose from. We are excited to add to P.E.I.'s product offerings, so that consumers can have the cannabis premium experiences they deserve," he added.

Sundial's high-quality products will be available in all four P.E.I. Cannabis locations, as well as on its e-commerce platform. Sundial's entrance into the P.E.I. market will begin with its Sundial brand which will offer five product lines: Calm, Ease, Flow, Lift and Spark. Each product is mindfully grown in small batches and nurtured by master growers to cultivate consistent high-quality cannabis that gives consumers a tailored experience.

The first products available to P.E.I. consumers will be Lemon Riot and Citrus Punch, two upbeat sativa-dominant hybrid strains under Sundial's Lift product line. Products from the Lift series aim to improve mood and encourage social interactions.

Sundial is also the proud owner of the premium cannabis brand Top Leaf, which is expected to be available in P.E.I. in the near future. Top Leaf is industry recognized and supported by award-winning cultivars and loyal consumers.

Geyser Brands Inc. (formerly Kanzen Capital Corp.) (TSX-V: GYSR) announced that it has signed a definitive joint venture agreement with Factory Brewing Ltd. (DBA "Craft Collective") to jointly develop, manufacture, market, and sell non-alcoholic cannabis-infused beverage brands in Canadian markets in two phases.

Pursuant to the terms of the JV Agreement, the Joint Venture will be structured as a new company, with two standing committees for the purpose of collaboration and cooperation on research, development and commercialization of its products. The first committee will be dedicated to identifying, developing and testing formulations for commercialization. The second committee will be dedicated to identifying and evaluating brands, including those brands owned by the Company and Craft Collective, for commercialization. Each committee will be comprised of 3 members from each of Geyser Brands and Craft Collective with the necessary expertise for each committee's mandate, with the Company appointing the Chair of each committee. The resulting NewCo will combine the craft beverage manufacturing, marketing and distribution expertise from Craft Collective with Geyser Brands' cannabis expertise, including leveraging its licensed producer facility, formulation expertise, and distribution channels.

Under the terms of the JV Agreement, the NewCo will immediately commence developing multiple product formulations and branding for both cannabis and non-cannabis products for introduction into the Canadian market. Craft Collective and NewCo will enter into a mutually agreeable non-cannabis product manufacturing and sales agreement in which Newco will outsource to Craft Collective the manufacturing and distribution of its non-cannabis products. Production of non-cannabis products will take place at Craft Collectives' facility in Vancouver, British Columbia. Upon receipt of regulatory approval for the production of cannabis products, Craft Collective and NewCo will use commercially reasonable efforts to enter into a definitive agreement in connection with the day to day management of the NewCo by Craft Collective, on terms and conditions mutually agreeable and customary in a transaction of this nature. Subject to the terms of the JV Management Agreement, all cannabis products will be manufactured at Geyser Brands' licensed facility in Port Coquitlam, British Columbia.

Pursuant to the terms of the JV Agreement, Geyser Brands will have a 75% interest in the NewCo, with Craft Collective's 25% interest being reserved and issued upon completion of certain conditions outlined in the JV Agreement, including receipt of regulatory approval for the production of cannabis products, the execution of the JV Management Agreement and the execution of a mutually agreeable shareholder agreement . In the event the Issue Conditions are not satisfied or waived by Geyser Brands on or before December 31, 2019, or such other date as mutually agreed by the parties, there will be no obligation for NewCo to issue any interest to Craft Collective.

Geyser Brands CEO, Andreas Thatcher commented, "Geyser Brands continues to build and lead the way in establishing its position as a health and wellness CPG company that gives lift to products with the addition of cannabis. Partnering with Craft Collective and jointly leveraging our unique areas of expertise will allow both parties to enter this emerging market and develop high-quality non cannabis and cannabis-infused beverages for the consumable cannabis market."

Craft Collective CEO, Andrew Harris stated, "This joint venture between Craft Collective and Geyser Brands marks an exciting milestone for our company as we continue to release innovative beverage brands to market. We look forward to launching impactful products through this combination of our expertise."

Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabis worldwide, announced the launch of Ready for Edibles, a national bilingual campaign dedicated to educating new and experienced cannabis consumers on responsible consumption and safe storage of edibles products before  they become available for sale in December.                                             
In the visual style of Not Safe For Work (NSFW)¸the campaign creative will depict blurred images of cookies, gummies and other edibles products stamped with the wording: ADULTS ONLY, stating "Edibles are coming and they're not for kids. Ask a budtender or learn more at www.readyforedibles.com" 
The campaign can be seen at cannabis retail outlets across Canada and will be complemented online with digital assets as well as other out-of-home opportunities to connect with consumers.   
"The roll-out of Aurora's next generation of high-quality cannabis products is very exciting and we are proud to be able to offer new forms like vapes, concentrates and edibles," said Terry Booth, CEO of Aurora. "We want to make sure consumers have the information they need to understand the differences in these products, how to consume them responsibly, and most importantly, that they should be kept away from children and pets."
Educational content will also focus on identifying signs of over-consumption, understanding the differences in onset times and effects, cautions around mixing with alcohol and driving while intoxicated. All of Aurora's NextGen cannabis products, including cookies, gummies, chocolates and mints, will include the certified, lab-tested concentration of THC and CBD.

One World Pharma Inc. (OTC: OWPC), a fully licensed pure-play cannabis and hemp ingredient producer in Colombia, announced the upcoming launch of the cannabis industry’s first ‘Cannabis Futures’ program at their growing operations in Colombia. OWP’s program is designed to support and fuel projected global cannabis industry growth by allowing manufacturers to fix their price in advance for cannabis and hemp derived ingredients produced by OWP at space specifically allocated to each specific manufacturer at OWP’s cultivation facilities in Colombia. The commoditized approach to sourcing hemp and cannabis ingredients anticipates and recognizes the natural maturity of the legal cannabis market and offers manufacturers of consumer-packaged goods (CPG) an easy way to enter the cannabis products market with a consistent supply of ingredients and predictable pricing.

With the cannabis industry predicted to continue to rapidly expand, scalability is an imperative in cannabis. One World Pharma believes that the future of cannabis is as a commodity, similar to coffee beans or orange juice where ideal ingredients are grown and sold to major consumer brands. While other cannabis companies have focused on being vertical plays spanning from seed to customer-facing dispensaries, One World Pharma is a pure-play cannabis business focused on one thing- supplying high quality hemp and cannabis derived ingredients to consumer brands. The upcoming launch of its Cannabis Futures program will provide these brands with predictable pricing for consistent, high-quality cannabis ingredients that allow them to keep their retail product offering consistent both in the deliverable and pricing.

“At its core, One World Pharma isn’t just a cannabis company, we’re an ingredients company,” said Chief Executive Officer, Craig Ellins. “Cannabis is now a commodity just like coffee or soybeans. We’re not interested in competing with the big players getting into branded cannabis products. Instead, we want to supply and enable them. Our Cannabis Futures program will provide major beverage companies, foods companies, cosmetic companies and any other enterprise looking to combine cannabis-based ingredients with their product offering with a streamlined path to enter the cannabis market.”

The Futures program will allow One World Pharma’s customers to commit to purchase a fixed amount of hemp and cannabis derived ingredients that will be grown and processed specifically to their unique requirements on land exclusively dedicated to them. This will allow One World Pharma to offer these customers a predetermined, consistent price for this future product. Customers will be able to lock in stable pricing while One World Pharma will be able to more accurately predict its own recurring revenue and optimize its growing operations.

In the future, One World Pharma believes that this model could lead to the development of a global cannabis commodities exchange. “We want to be part of creating the long-term global financial and supply chain structures for the cannabis industry,” said Ellins. “Partnership is one of our core values and the foundation of our socially responsible practices. We believe that strong infrastructure and systems will benefit the entire industry.”

One World Pharma’s socially responsible partnerships with indigenous communities and local farmers in Colombia will offer scalability to support its Cannabis Futures program and service the needs of large manufacturers, while blending ancestral techniques with state-of-the-art technology in one of the most ideal cannabis-growing locations in the world.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   


Subscribe to the new cannabis podcast series:


To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Follow us on Social Media

Contact Investorideas.com
800-665-0411

  



Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory


SinglePoint (OTCQB: $SING) Launches Wholly Owned Brand 1606 Original Hemp


SinglePoint (OTCQB: $SING) Launches Wholly Owned Brand 1606 Original Hemp
SinglePoint introduces - 1606 Original Hemp


PHOENIX - October 31, 2019 (Investorideas.com Newswire) SinglePoint, Inc. (OTCQB:SING) has launched into the smokable hemp market, releasing its wholly owned brand, 1606 Original Hemp. The brand will carry a variety of smokable hemp products. Recently, the company presented at NACS 2019 and had a phenomenal response driving the creation of 1606. To date, the company has shipped orders to convenience store owners with a collective 250 doors and has interest from over 100 parties that collectively have over 15,000 doors.


SinglePoint (SIGN): Original Hemp 1606 Cigarettes

The name derives from the first hemp crop planted in 1606 in North America. SinglePoint has planned to expand the brand quickly through retail, distribution, and a new ecommerce site currently in development.
In today's world, hemp is becoming very popular. The use of hemp has evolved into diverse products such as lotions, oils, food, beverages, and cigarettes. Smokable hemp is a developing trend, but is it a good way to consume the cannabinoid? Here's what you need to know:
Hemp vs. Marijuana
Hemp and marijuana are both part of the cannabis family. However, hemp will not get you high unlike marijuana, which is known for its psychoactive effects. Marijuana has high levels of THC, containing anywhere from 5%-35% whereas hemp has less than 0.3% THC. Hemp contains high cannabidiol (CBD) content which is not psychoactive. Smoking hemp is a positive alternative to marijuana, "You get the same taste, the same psychological feeling of smoking a joint, but without the high."
Replacing Tobacco
Pure American Hemp cigarettes (link) are nicotine and tobacco free. Some research suggests that smoking hemp cigarettes could be a potential tool to replace tobacco and nicotine addictions. According to a Brightfield Group survey of more than 5,000 CBD users in the U.S.:
  • 24% have used it to help quit smoking.
  • Quitters are often replacing cigarettes
  • with either smokable hemp or vaping.
  • 41% of quitters have entirely replaced
  • tobacco with hemp CBD.
Google trends reveals over the last year that hemp was researched more often than tobacco and nicotine.
Initial Research
Initial research has shown CBDs ability to reduce cigarette consumption. Researchers at University College London conducted a study of 24 smokers. Each were given an inhaler with CBD or placebo. For one week they were to use the inhaler when they had the urge to smoke. Those with placebo had no difference in cigarettes smoked, those with the CBD inhaler significantly reduced the number of cigarettes smoked by 40%.
The Alternative Market
The Alternative Market has continued to grow drastically, 35%, from 2019 to 2018 while cigarettes stayed steady at 3.1%. With the addition of hemp cigarettes and the recent vape scare, many assume the alternative market will continue growing as people look for a "healthier for you" alternative to cigarettes.
The Future
BDS Analytics and Arcview Market Research projects that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024 while New York-based investment bank Cowen & Co, estimates that the market could pull in $15 billion by 2025. The smokable hemp market currently represents approximately 2% of the overall CBD market, but with a 250% growth from 2017 to 2018, Brightfield Group, a Chicago-based cannabis market research firm, identifies dried and smokable hemp flowers as one of the fastest-growing segments of the CBD market.
About SinglePoint, Inc.
SinglePoint, Inc (SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services and blockchain solutions. Through acquisitions into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued companies, thereby providing a rich, diversified holding base. Through SingleSeed, the company is providing products and services to the cannabis industry.
Connect on social media at:
For more information visit: www.SinglePoint.com
Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
Corporate Communication
SinglePoint Inc.
855-711-2009
investors@SinglePoint.com
SinglePoint.com

SinglePoint (SING) is a featured stock on Investorideas.com

More info on SING at Investorideas.com Visit: https://www.investorideas.com/CO/SING/


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. For Disclosure purposes SinglePoint Inc (OTCQB: SING) is a paid  annual news and social media company on Investorideas.com.  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp and  https://www.investorideas.com/About/News/Clientspecifics.asp . Learn more about our prices for publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories





Wednesday, 30 October 2019

Investorideas.com - Drug Policy Alliance Statement on USDA Industrial Hemp Rules

Investorideas.com - Drug Policy Alliance Statement on USDA Industrial Hemp Rules

www.investorideas.com - news that inspires big ideas

#Cannabis Industry Continues Global Expansion from #Israel to the EU; (CSE: $IPOT.C) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (TSXV: $PCLO.V)


#Cannabis Industry Continues Global Expansion from #Israel to the EU; (CSE: $IPOT.C) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (TSXV: $PCLO.V)

Point Roberts WA, Delta, BC – October 30, 2019 - Investorideas.com, a leading investor news resource covering cannabis and hemp stocks releases a sector snapshot reporting on the continued international expansion of the cannabis industry and how it’s leading to a global cannabis infrastructure.


A recent article reporting on the growth of the global cannabis industry notes, “Fully 185 countries are signatories to the United Nations’ Single Convention on Narcotic Drugs of 1961, which prohibits cannabis as a drug that can be abused and cause ill effects, without bringing a substantial therapeutic advantage. Each signatory’s laws must reflect the Convention; that is the case for the US’ Controlled Substances Act of 1971. Countries that have legalized cannabis are flouting the convention, and some, such as Canada, admit that openly.”

“Thanks to changing public perceptions, moves such as Canada’s, ongoing research on health benefits and risks, and the urging of the World Health Organization—in 2019 it came out in favor of less restrictive control of cannabis and of removing prohibitions for pure CBD and CBD preparations containing no more than .2% THC—the United Nations has said it will revisit cannabis under the Single Convention. It should be noted, however, that amending the convention is difficult with so many members involved.”
“Medical use of cannabis is and will be accepted around the world a lot more quickly than recreational use,” says Mario Torres of Brazeau Seller Law (Ottawa, Ontario, Canada). “People are not enthused about prohibiting medical care. They don’t want to disallow access to the only thing that may stop epileptic seizures in children or is part of a patient’s treatment plan.” Medical use is becoming more acceptable even in very conservative countries like South Korea and Thailand, which have legalized cannabis for medical purposes.

Recent news headlines look to Israel saying,” Israel is at the forefront of cannabis tech. The country, which produces more pharmaceutical cannabis than just about anywhere else, is poised to become a leading exporter.”

Recently listed on the CSE, Isracann Biosciences Inc. (CSE: IPOT) is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. The Company (formerly Atlas Blockchain Group Inc.), recently provided an operative overview and update regarding facility development activities in Israel.

Concurrent to and as part of the Company’s recent listing on the Canadian Securities Exchange it had satisfied the escrow release conditions for the net proceeds of its highly successful CAD$10.1 million financing efforts which bolstered an already healthy cash position.

This positions the company to immediately accelerate its planned Phase One Facility Design and Construction Services Program which consists of finalization of greenhouse facility design for cannabis cultivation and production in accordance with an existing technical specifications strategy; to rapidly advance greenhouse and related facility construction per the design; ensure adequate controls are in place against any diversion, theft and loss of cannabis products per regulatory standards; and ensure compliance with other protective security, health, and safety requirements in accordance with Israeli regulations.

To date, Isracann has entered into agreements for the development of medical cannabis cultivation projects with regional stakeholders holding preliminary breeding and cultivation licenses issued by the Israeli Ministry of Health. The regional stakeholder is required to renew these licenses each year and further bears the cost of electricity, property and related land taxes and are bound to working with Isracann to obtain the required licenses and to participate in the construction of the greenhouses.

Isracann ‘s CEO, Darryl Jones notes, “We are very pleased to have achieved our very important initial milestone targets with the CSE listing of our ticker symbol “IPOT” and to confirm our accelerated investment plans in Israel are fully underway. We have lined up several key organizations and personnel and look forward to announcing a number of these key commercial agreements in the days and weeks ahead. We thank all our supporters for their belief in us, and in our belief that the Israeli agricultural sector will provide a huge leading role in positioning the Isracann brand as market leaders in the massive and underserved European cannabis marketplace.”

In related news, the Company welcomes the recent appointment of Irit Arbel, Ph.D. to its Board of Directors. Dr. Arbel brings significant senior multidisciplinary biopharma and governance experience to Isracann’s board. She serves as CEO, Co-Founder and Director of Neurocords Ltd., a company focused on developing new treatments for peripheral and spinal cord regeneration, and previously served as Director and President of Brainstorm Cell Therapeutics, and as Executive Vice President of Research and Development at Savicell Diagnostic, a biotechnology company. Dr. Arbel previously served as Chairperson of Real Aesthetics, a company specializing in cellulite ultrasound treatment, and BRH Medical, a developer of medical devices for wound healing. She was also Director of M&A at RFB Investment House, a private investment firm focusing on early-stage technology-related companies. Previously, Dr. Arbel was President and Chief Executive Officer of Pluristem Life Systems, a biotechnology company, and prior to that as Israeli Sales Manager of Merck, Sharp & Dohme, a pharmaceutical company. Dr. Arbel earned her Ph.D. in 1997 in Neurobiology, after performing research in the area of MS. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel’s Institute of Technology.

Avicanna Inc.(TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, recently announced that Santa Marta Golden Hemp S.A.S., its majority owned subsidiary, has completed commercial exports of its Aureus™ brand of CBD-based products to South Africa and the United Kingdom.

The Aureus brand of products include an organic and sustainable line of plant-derived active pharmaceutical ingredients ("APIs") and bulk CBD formulations developed by Avicanna in collaboration with SMGH and Sativa Nativa S.A.S. ("Sativa Nativa"), which is also a majority owned subsidiary of Avicanna. These initial sales included the export of CBD isolate and 4% bulk formulation for CBD oil sublingual sprays. Each of the above exports has been completed in accordance with all applicable laws in the Jurisdictions.

Aras Azadian, Avicanna's Chief Executive Officer, stated "We are excited to bring the Aureus brand of cannabinoid APIs to our international customers. We believe these initial sales further validate the brand's opportunities in these two countries, as well as the potential for us to actively market our APIs across the globe to manufacturers of CBD products. We believe the Aureus brand of API products will become a leader in organic and sustainable cannabinoid raw materials and the gold standard with respect to global quality controls, which we believe are necessary for the evolution of a worldwide cannabinoid industry.”

Avicanna is also looking into the Latin American market having announced the retail launch of its Pura Earth™ derma-cosmetics line of CBD products, which are now available at approximately 59 high-end retail locations throughout Colombia, including Blind Prestige beauty shops and Cromantic professional beauty markets.

Khiron Life Sciences Corp. (TSXV: KHRN) (OTC: KHRNF), a vertically integrated cannabis leader with core operations in Latin America, recently announced their entrance into the EU market having completed the EU cosmetic regulatory process for seven Kuida products, and received a "no objection" letter from TSXV with respect to distribution of these products in the UK.

Tejinder Virk, President, Khiron Europe, commented, "The fulfillment of EU cosmetic regulatory requirements allows the Company to bring our proven product line into the sophisticated and growing European skincare market, where we expect to rapidly build and grow Kuida's market share. We will initially focus on import and marketing in UK, with our first sales expected in Q1 2020, before expanding to Spain, Germany and the broader European market, subject to the specific requirements of individual member states and TSXV approval."

Kuida®, the first consumer brand of Khiron's wellness business unit, brings the benefits of cannabidiol (CBD) to a comprehensive portfolio of skin and body care products for women. Kuida was launched in Colombia in October 2018 through retail, wholesale and online channels and is now available nationwide and through e-commerce channels. As the Company expands Kuida® distribution in Europe, the brand will be a featured exhibitor at Cosmoprof Worldwide Bologna 2020, which attracted over 265,000 visitors in 2019 and is the largest such event to learn more about market leading products and to place orders.

The company also participated in the Open Parliament held by Senate of Mexico on the theme of "Towards Cannabis Regulation," which took place through August 2019 and September 2019. As a Latin American cannabis leader with a strong presence in Mexico, Khiron joined both open forum sessions and a committee of experts to engage in dialogue and provide input on the building blocks of the country's new regulatory framework.

PharmaCielo Ltd. (TSXV:PCLO) (OTC: PHCEF), whose anticipated acquisition of Australian Securities Exchange ("ASX") listed Creso Pharma will establish a global medicinal cannabis company positioned to rapidly develop new markets and grow sales in the expanded footprint served by the combined company, recently announced key developments in respect of its acquisition originally announced on June 6, 2019. Creso Pharma has informed the Company that it has received approval from the Supreme Court of Western Australia to convene meetings of its shareholders and listed option holders, and if thought fit, to approve the Schemes of Arrangement whereby PharmaCielo would acquire all of the issued and outstanding shares and listed options of Creso Pharma. The Meetings will be held on November 11, 2019, beginning at 10:00AM (Perth time).

The Board of Directors of Creso Pharma continue to unanimously recommend that Creso Pharma Shareholders and the Creso Pharma Optionholders vote in favour of the proposed Schemes of Arrangement, in the absence of a superior proposal for Creso Pharma.

David Attard, CEO of PharmaCielo commented, "PharmaCielo's acquisition of Creso Pharma, creates a combined company that has operational excellence across the value chain. The quality and scale of PharmaCielo's cultivation and extraction compliments Creso Pharma's product development and extensive developed global sales channels. With the Creso Pharma acquisition and our recently announced agreement to export CBD into the United States , 2020 is going to be an exciting year for PharmaCielo shareholders."
PharmaCielo expects that the combined company will be well-positioned to drive significant value for both existing PharmaCielo and Creso Pharma shareholders.

PharmaCielo has received conditional approval from the TSX Venture Exchange for the issuance of common shares of PharmaCielo to Creso Pharma Shareholders and Creso Pharma Optionholders in order to effect the Schemes of Arrangement. The effective date of the Schemes of Arrangement is expected to be November 13, 2019; and the closing date of the acquisition is expected to be November 22, 2019.

With the growing international acceptance of the cannabis industry, companies with strongly established infrastructure in key global trade areas will become more of an essential asset as the industry moves further towards global standards and sales.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining,  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Disclosure: this news article featuring CSE:  IPOT is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Social Media

Contact Investorideas.com
800-665-0411

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories




New Stocks to Watch in Tech (NASDAQ: $FROG) (NYSE: $SNOW), Cannabis (CSE: $MLCL.C) (OTC Pink: $GPOX) and Gaming (NASDAQ: $CRSR)

  New Stocks to Watch in Tech  ( NASDAQ: $FROG)  (NYSE: $SNOW), Cannabis (CSE: $MLCL.C)  ( OTC Pink: $GPOX) and Gaming (NASDAQ:  $CRSR)   Wa...